Patents by Inventor Gary K. Lee

Gary K. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED DISRUPTION OF T CELL AND/OR HLA RECEPTORS
    Publication number: 20230295563
    Abstract: Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Application
    Filed: October 21, 2022
    Publication date: September 21, 2023
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, David Paschon, Edward J. Rebar, Lei Zhang
  • GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2-CONTAINING PROTEIN (CISH) GENE
    Publication number: 20230272415
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted genetic modification of a CISH gene.
    Type: Application
    Filed: November 22, 2022
    Publication date: August 31, 2023
    Inventors: Anthony Conway, Gary K. Lee
  • Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
    Patent number: 11661611
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted genetic modification of a CISH gene.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: May 30, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gary K. Lee
  • LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESSION CASSETTES AND METHODS OF USE THEREOF
    Publication number: 20230119850
    Abstract: Described herein are constructs used for liver-specific expression of a transgene.
    Type: Application
    Filed: September 1, 2022
    Publication date: April 20, 2023
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Brigit E. Riley, Gary K. Lee
  • Targeted disruption of T cell and/or HLA receptors
    Patent number: 11512287
    Abstract: Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 29, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, David Paschon, Edward J. Rebar, Lei Zhang
  • TARGETED DISRUPTION OF THE T CELL RECEPTOR
    Publication number: 20220315932
    Abstract: Disclosed herein are methods and compositions for inactivating TCR genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.
    Type: Application
    Filed: May 19, 2022
    Publication date: October 6, 2022
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Liver-specific constructs factor VIII expression cassettes and methods of use thereof
    Patent number: 11452782
    Abstract: Described herein are constructs used for liver-specific expression of a transgene.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: September 27, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Brigit E. Riley, Gary K. Lee
  • TARGETED DISRUPTION OF THE MHC CELL RECEPTOR
    Publication number: 20220175839
    Abstract: Disclosed herein are methods and compositions for inactivating MHC genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
    Type: Application
    Filed: February 23, 2022
    Publication date: June 9, 2022
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Targeted disruption of the T cell receptor
    Patent number: 11352631
    Abstract: Disclosed herein are methods and compositions for inactivating TCR genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: June 7, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Targeted disruption of the MHC cell receptor
    Patent number: 11285175
    Abstract: Disclosed herein are methods and compositions for inactivating MEW genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 29, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Modulation of liver genes
    Patent number: 10960085
    Abstract: Described herein are compositions and methods for modulation of gene expression in the liver including modulation of PCSK9, TTR, SERPINA1, KLKB1 and/or HAO1.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: March 30, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gary K. Lee, David Paschon, Lei Zhang
  • MODULATION OF LIVER GENES
    Publication number: 20210060179
    Abstract: Described herein are compositions and methods for modulation of gene expression in the liver including modulation of PCSK9, TTR, SERPINA1, KLKB1 and/or HAO1.
    Type: Application
    Filed: November 12, 2020
    Publication date: March 4, 2021
    Inventors: Anthony Conway, Gary K. Lee, David Paschon, Lei Zhang
  • Liver-specific constructs and methods of use thereof
    Patent number: 10828376
    Abstract: Described herein are constructs used for liver-specific expression of a transgene.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: November 10, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Brigit E. Riley, Gary K. Lee
  • DELIVERY METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED GENOME ENGINEERING
    Publication number: 20200102577
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell.
    Type: Application
    Filed: September 6, 2019
    Publication date: April 2, 2020
    Inventors: GARY K. LEE, Brigit E. Riley, Susan J. St. Martin, Thomas Wechsler
  • TARGETED DISRUPTION OF THE MHC CELL RECEPTOR
    Publication number: 20200069735
    Abstract: Disclosed herein are methods and compositions for inactivating MEW genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
    Type: Application
    Filed: November 12, 2019
    Publication date: March 5, 2020
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Targeted disruption of the MHC cell receptor
    Patent number: 10500229
    Abstract: Disclosed herein are methods and compositions for inactivating MHC genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: December 10, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Delivery methods and compositions for nuclease-mediated genome engineering
    Patent number: 10450585
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: October 22, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gary K. Lee, Brigit E. Riley, Susan J. St. Martin, Thomas Wechsler
  • LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESSION CASSETTES AND METHODS OF USE THEREOF
    Publication number: 20190151472
    Abstract: Described herein are constructs used for liver-specific expression of a transgene.
    Type: Application
    Filed: October 26, 2018
    Publication date: May 23, 2019
    Inventors: Brigit E. Riley, Gary K. Lee
  • LIVER-SPECIFIC CONSTRUCTS AND METHODS OF USE THEREOF
    Publication number: 20190142970
    Abstract: Described herein are constructs used for liver-specific expression of a transgene.
    Type: Application
    Filed: October 18, 2018
    Publication date: May 16, 2019
    Inventors: Brigit E. Riley, Gary K. Lee
  • GENETIC MODIFICATION OF CYTOKINE INDUCIBLE SH2-CONTAINING PROTEIN (CISH) GENE
    Publication number: 20190136261
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted genetic modification of a CISH gene.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 9, 2019
    Inventors: Anthony Conway, Gary K. Lee